drugset / Trial / NCT05535738
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
Non-randomizedSequentialOpen-labelBasic science
Summary
The purpose of this study is to answer: how do inflammation and anti-inflammatory skin therapies work in the skin? Inflammation is a protective response from the body's immune system to injury, disease, or irritation. It is a process by which your body's white blood cells and the things they make protect you from infection from outside invaders such as bacteria and viruses.
Timeline
- Start
- 2022-11-15
- Primary completion
- 2027-01-01
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | — |
| Subject | Canakinumab | Monoclonal antibody | 150 mg | — |
| Subject | Dupilumab | Monoclonal antibody | 300 mg | — |
| Subject | Fluticasone propionate | Other / unclassified | 0.005 % | — |
| Subject | Guselkumab | Monoclonal antibody | 100 mg | — |
| Subject | Sarilumab | Monoclonal antibody | 200 mg | — |
| Subject | Triamcinolone Acetonide | Other / unclassified | 0.1 % | — |
| Subject | Ustekinumab | Monoclonal antibody | 45 mg | — |
| Subject | betamethasone valerate | Small molecule | 0.1 % | — |